Singular Genomics Systems Statistics
Share Statistics
Singular Genomics Systems has 2.51M shares outstanding. The number of shares has increased by -96.6% in one year.
| Shares Outstanding | 2.51M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.05% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.51M |
| Failed to Deliver (FTD) Shares | 322 |
| FTD / Avg. Volume | 0.68% |
Short Selling Information
The latest short interest is 71.17K, so 2.83% of the outstanding shares have been sold short.
| Short Interest | 71.17K |
| Short % of Shares Out | 2.83% |
| Short % of Float | 4.72% |
| Short Ratio (days to cover) | 2.3 |
Valuation Ratios
The PE ratio is -0.35 and the forward PE ratio is -0.72.
| PE Ratio | -0.35 |
| Forward PE | -0.72 |
| PS Ratio | 11.5 |
| Forward PS | 4.9 |
| PB Ratio | 0.19 |
| P/FCF Ratio | -0.45 |
| PEG Ratio | n/a |
Enterprise Valuation
Singular Genomics Systems Inc. has an Enterprise Value (EV) of 92.55M.
| EV / Earnings | -0.98 |
| EV / Sales | 31.79 |
| EV / EBITDA | -1.07 |
| EV / EBIT | -0.9 |
| EV / FCF | -1.24 |
Financial Position
The company has a current ratio of 10.51, with a Debt / Equity ratio of 0.09.
| Current Ratio | 10.51 |
| Quick Ratio | 9.77 |
| Debt / Equity | 0.09 |
| Total Debt / Capitalization | 8.52 |
| Cash Flow / Debt | -4.42 |
| Interest Coverage | -93.37 |
Financial Efficiency
Return on equity (ROE) is -0.53% and return on capital (ROIC) is -40.43%.
| Return on Equity (ROE) | -0.53% |
| Return on Assets (ROA) | -0.36% |
| Return on Capital (ROIC) | -40.43% |
| Revenue Per Employee | 11.42K |
| Profits Per Employee | -371.84K |
| Employee Count | 255 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.26 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 56.99% in the last 52 weeks. The beta is 1.51, so Singular Genomics Systems 's price volatility has been higher than the market average.
| Beta | 1.51 |
| 52-Week Price Change | 56.99% |
| 50-Day Moving Average | 18.44 |
| 200-Day Moving Average | 12.96 |
| Relative Strength Index (RSI) | 47.49 |
| Average Volume (20 Days) | 47.30K |
Income Statement
In the last 12 months, Singular Genomics Systems had revenue of $2.91M and earned -$94.82M in profits. Earnings per share was $-39.08.
| Revenue | 2.91M |
| Gross Profit | -558.00K |
| Operating Income | -102.80M |
| Net Income | -94.82M |
| EBITDA | -86.50M |
| EBIT | -102.80M |
| Earnings Per Share (EPS) | -39.08 |
Balance Sheet
The company has $16.23M in cash and $75.29M in debt, giving a net cash position of -$59.05M.
| Cash & Cash Equivalents | 16.23M |
| Total Debt | 75.29M |
| Net Cash | -59.05M |
| Retained Earnings | -337.60M |
| Total Assets | 186.55M |
| Working Capital | 112.20M |
Cash Flow
In the last 12 months, operating cash flow was -$73.65M and capital expenditures -$970.00K, giving a free cash flow of -$74.62M.
| Operating Cash Flow | -73.65M |
| Capital Expenditures | -970.00K |
| Free Cash Flow | -74.62M |
| FCF Per Share | -30.75 |
Margins
Gross margin is -19.17%, with operating and profit margins of -3.53K% and -3.26K%.
| Gross Margin | -19.17% |
| Operating Margin | -3.53K% |
| Pretax Margin | -3.26K% |
| Profit Margin | -3.26K% |
| EBITDA Margin | -2.97K% |
| EBIT Margin | -3.53K% |
| FCF Margin | -2.56K% |
Dividends & Yields
OMIC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -195.4% |
| FCF Yield | -148.53% |
Analyst Forecast
The average price target for OMIC is $10.75, which is -46.2% lower than the current price. The consensus rating is "Hold".
| Price Target | $10.75 |
| Price Target Difference | -46.2% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jun 26, 2024. It was a backward split with a ratio of 1:30.
| Last Split Date | Jun 26, 2024 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | -3.3 |
| Piotroski F-Score | 3 |